| 本文已被：浏览 1477次 下载 1514次 |
码上扫一扫！ |
| 产气荚膜梭菌ε毒素突变体的表达及免疫保护力评价 |
| 杜吉革,张秀坤,朱真,薛麒,李启红,印春生,彭小兵,王磊,姚文生,康凯,陈小云 |
|
|
| (中国兽医药品监察所) |
|
| 摘要: |
| 为获得产气荚膜梭菌ε毒素的重组突变体,并评价其毒力及免疫原性。对已知的D型产气荚膜梭菌ε毒素(ETX)编码基因进行优化设计,并将第106位组氨酸突变为脯氨酸,经人工合成获得基因片段GETXH106P。将GETXH106P克隆至原核表达载体pET30a-(＋)中进行表达与纯化,从而获得重组蛋白rETXH106P。利用Western blot方法检测rETXH106P与D型产气荚膜梭菌抗血清的反应性,并检测其对犬肾细胞系(MDCK细胞)以及小鼠的毒力。随后,将rETXH106P与Montanide ISA 201佐剂混合乳化制备疫苗,免疫4只健康家兔,按照《中华人民共和国兽药典》(2015年版)规定的方法检测一免及二免后兔血清的中和抗体效价。结果表明,rETXH106P为可溶性表达,通过灰度扫描,其可溶性表达量比例可达30%；该重组蛋白能与D型产气荚膜梭菌毒素抗血清反应；细胞毒性试验结果显示,100μg/ml的重组蛋白仍无细胞毒性；小鼠安全性实验结果显示,6.25×106ng/kg剂量的重组蛋白对小鼠仍无致死性；每毫升的一免抗血清可中和450~700个小鼠MLD、二免抗血清可中和3000～4000个小鼠MLD的D型产气荚膜梭菌毒素；用1个家兔MLD的D型产气荚膜梭菌毒素攻毒后,对照组家兔4/4死亡,免疫组家兔4/4保护。以上结果表明,产气荚膜梭菌rETXH106P重组蛋白毒力基本消失,且保留了良好的免疫原性,是D型产气荚膜梭菌病基因工程亚单位疫苗的理想候选抗原蛋白。 |
| 关键词: 产气荚膜梭菌ε毒素 突变 重组表达 毒力 抗原性 |
| DOI： |
| 投稿时间：2018-01-12修订日期：2018-06-11 |
| 基金项目:科技部十三五“牛羊重要疫病免疫防控新技术研究”重点专项子课题(2017WFD0500903)；中国兽医药品监察所所级课题(201702)。 |
|
| Expression and Evaluation of Protective Efficacy of Clostridium perfringens ε toxin mutant |
|
| (China Institute of Veterinary Drug Control,Beijing 100081,China) |
| Abstract: |
| This experiment was conducted to obtain recombinant mutant of Clostridium perfringens ε toxin and subsequently evaluate the virulence and immunogenicity of the recombinant toxin. The ε toxin gene of Clostridium perfringens type D strain, GETXH106P, using optimized codons was synthesized based on the sequence reported. At the same time, H106 was substituted with proline. Then，GETXH106P was cloned into prokaryotic expression vector pET3a-(＋) to get the recombinant protein, rETXH106P, following with purification. The reactivity of rETXH106P with antiserum of Clostridium perfringens type D was detected by Western blot. Meanwhile, Canine Kidney (MDCK) cell and mice were used to detect the virulence of rETXH106P. According to the method prescribed in Chinese Veterinary Pharmacopoeia (2015), four rabbits were immunized with rETXH106P emulsified with oil adjuvant of ISA 201 to prepare antiserum and detect the neutralizing titer of antiserums after first and twice immunization. The results showed that rETXH106P was expressed at a high level as soluble form with a ratio about 30% by gray scale scanning, and it could react with the antiserum of Clostridium perfringens type D. For MDCK cell, there were no apparent cytopathic effect (CPE) incubated with rETXH106P of 100μg/ml. At the same time, rETXH106P with the injection volume of 6.25×106 ng/kg was not fatal to ICR mice. After the first immunization, sera from rabbits immunized with rETXH106P could neutralize 450-700 mice MLD Clostridium perfringens type D toxin per ml, and 3000-4000 mice MLD after twice immunization. Moreover, rabbits in rETXH106P immunized group fully survived at the dose of 1 rabbit MLD of Clostridium perfringens type D toxin challenge, whereas all of the rabbits died (4/4) in the control groups. The results suggest that rETXH106P without virulence retains the good immunogenic antigen, which is an ideal candidate antigen for genetic engineering subunit vaccine of Clostridium perfringens. |
| Key words: Clostridium perfringens ε toxin mutation recombinant expression virulence antigenicity |
